NASDAQ:BCDA

BioCardia Stock Forecast, Price & News

$3.68
0.00 (0.00 %)
(As of 04/22/2021 04:30 PM ET)
Add
Compare
Today's Range
$3.60
Now: $3.68
$3.83
50-Day Range
$3.42
MA: $4.08
$4.61
52-Week Range
$1.91
Now: $3.68
$8.60
Volume58,626 shs
Average Volume281,621 shs
Market Capitalization$60.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
BioCardia logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BCDA
CUSIPN/A
CIKN/A
Phone650-226-0120
Employees24
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$710,000.00
Book Value$0.35 per share

Profitability

Net Income$-14,710,000.00
Net Margins-5,103.95%

Miscellaneous

Market Cap$60.13 million
Next Earnings Date5/21/2021 (Estimated)
OptionableNot Optionable

Headlines

BioCardia (NASDAQ:BCDA) Given Neutral Rating at Dawson James
April 22, 2021 |  americanbankingnews.com
BioCardia (NASDAQ:BCDA) Downgraded by Dawson James
April 17, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.30 out of 5 stars

Medical Sector

582nd out of 2,024 stocks

Biological Products, Except Diagnostic Industry

81st out of 177 stocks

Analyst Opinion: 3.3Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$3.68
0.00 (0.00 %)
(As of 04/22/2021 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioCardia (NASDAQ:BCDA) Frequently Asked Questions

Is BioCardia a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioCardia stock.
View analyst ratings for BioCardia
or view top-rated stocks.

What stocks does MarketBeat like better than BioCardia?

Wall Street analysts have given BioCardia a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioCardia wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BioCardia?

BioCardia saw a increase in short interest in March. As of March 31st, there was short interest totaling 458,300 shares, an increase of 68.4% from the March 15th total of 272,200 shares. Based on an average daily trading volume, of 295,700 shares, the days-to-cover ratio is currently 1.5 days.
View BioCardia's Short Interest
.

When is BioCardia's next earnings date?

BioCardia is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for BioCardia
.

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) posted its quarterly earnings data on Monday, March, 29th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.15. BioCardia had a negative net margin of 5,103.95% and a negative trailing twelve-month return on equity of 496.87%.
View BioCardia's earnings history
.

How has BioCardia's stock price been impacted by COVID-19 (Coronavirus)?

BioCardia's stock was trading at $3.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BCDA shares have increased by 2.5% and is now trading at $3.68.
View which stocks have been most impacted by COVID-19
.

When did BioCardia's stock split? How did BioCardia's stock split work?

Shares of BioCardia reverse split on Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 2nd 2017. An investor that had 100 shares of BioCardia stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for BCDA?

3 equities research analysts have issued 12 month target prices for BioCardia's stock. Their forecasts range from $7.00 to $11.50. On average, they anticipate BioCardia's stock price to reach $9.25 in the next year. This suggests a possible upside of 151.4% from the stock's current price.
View analysts' price targets for BioCardia
or view top-rated stocks among Wall Street analysts.

Who are BioCardia's key executives?

BioCardia's management team includes the following people:
  • Dr. Peter A. Altman, CEO, Pres & Director (Age 54, Pay $362.7k)
  • Mr. David McClung, Chief Financial Officer (Age 58, Pay $302.25k)
  • Mr. Phil Pesta, VP of Operations (Age 55)
  • Dr. Ian McNiece Ph.D., Chief Scientific Officer (Age 67)
  • Mr. Edward M. Gillis, Sr. VP of Devices (Age 59)
  • Dr. Sujith Shetty, Chief Medical Officer

Who are some of BioCardia's key competitors?

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), (SAND), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), (ANIX), American Manganese (AMY) and (ALT).

When did BioCardia IPO?

(BCDA) raised $51 million in an initial public offering on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

What is BioCardia's stock symbol?

BioCardia trades on the NASDAQ under the ticker symbol "BCDA."

How do I buy shares of BioCardia?

Shares of BCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCardia's stock price today?

One share of BCDA stock can currently be purchased for approximately $3.68.

How much money does BioCardia make?

BioCardia has a market capitalization of $60.13 million and generates $710,000.00 in revenue each year. The company earns $-14,710,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis.

How many employees does BioCardia have?

BioCardia employs 24 workers across the globe.

What is BioCardia's official website?

The official website for BioCardia is www.biocardia.com.

Where are BioCardia's headquarters?

BioCardia is headquartered at 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070.

How can I contact BioCardia?

BioCardia's mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The company can be reached via phone at 650-226-0120 or via email at [email protected]


This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.